Five Prime, Bristol-Myers deal
The partners will jointly evaluate a combination of Bristol-Myers’ Opdivo nivolumab and Five Prime’s FPA008 in a Phase Ia/Ib trial to treat non-small cell lung cancer (NSCLC), melanoma, head and neck cancer, pancreatic cancer, colorectal cancer and malignant glioma. Five Prime will receive $30 million up front and funding for the study, which Five Prime expects to begin by 2H15. Each partner has an exclusive opt-in right if the other proposes to study combinations of programmed cell death 1 ( PDCD1; PD-1; CD279) or programmed cell death 1 ligand 1 ( PD-L1; B7-H1; CD274) antagonists with anti-colony-stimulating factor 1 receptor ( CSF1R; C-FMS; CD115) antagonists in additional tumor types. If Five Prime seeks a partner for FPA008, BMS will have a right of first refusal for three months. ...